Results for “”

Entry Author Date Location
SeaGen Adds Five Prime Therapeutics Antibodies in Licensing Deal 02/20/20 Seattle
Spruce Bio Raises $88M for Clinical Tests of Rare Endocrine Disease Drug 02/20/20 San Francisco
Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test 02/18/20 San Francisco
Imara Reveals IPO Plan as Sickle Cell Drug Advances in the Clinic 02/18/20 Boston
Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More 02/14/20 National
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks 02/13/20 National
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer 02/12/20 San Francisco
Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened. 02/11/20 National
Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s 02/10/20 National
Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer 02/06/20 San Francisco
Coda Bio Acquires Drug Candidates to Pair With Engineered Receptors 02/06/20 San Francisco
Aimmune Gets $200M From Nestlé; Licenses Food Allergy Drug Candidate 02/05/20 San Francisco
Merck Charts an R&D-Focused Course Starting With a $6.5B Spinoff 02/05/20 New York
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA 02/04/20 National
Verily, Santen See Ophthalmology Opportunity Via New Joint Venture 02/04/20 San Francisco
$750M Fund Looks to Software Sector to Drive Future of Biotech 02/04/20 National
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy 01/31/20 San Francisco
Arcutis Bio Raises $159M in Upsized IPO to Test Skin Disease Drugs 01/31/20 San Diego
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More 01/31/20 National
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14 01/30/20 San Francisco
Black Diamond’s Upsized IPO Raises $201M to Advance Its Cancer Drug R&D 01/30/20 Boston
Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report 01/28/20 National
Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More 01/24/20 National
Emendo Eyes the Clinic for CRISPR Therapy That Makes Single-Gene Edits 01/22/20 New York
CEOs of Women’s Health Companies Fight to Open Investment Floodgates 01/22/20 San Diego
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers 01/17/20 San Francisco
Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More 01/17/20 National
FDA Panel Votes Down Nektar Opioid Painkiller, Asks for More Data 01/14/20 National
Generation Bio Pockets $110M for Next Wave of Gene Therapy, IPO Plans 01/13/20 Boston
Allogene, SpringWorks to Test Drug Combo in Multiple Myeloma Trial 01/13/20 San Francisco
Page 1 of 101 next page »